What Is Interstitial Lung Disease?

Apr 14, 2022 Source: Cainiu Health
Dr. Li Man
Introduction
Interstitial lung disease (ILD) is a type of pulmonary disorder. Currently, its detection rate has increased due to the widespread use of high-resolution computed tomography (HRCT). The tissue between alveoli—termed the interstitium—contains blood vessels, lymphatic fluid, and other cells, including proliferating connective tissue. When pathological changes occur in the interstitium—such as increased elastic fibers, vascular proliferation, or inflammatory cell infiltration—the condition is referred to as interstitial lung disease.

Lung diseases are not unfamiliar to people; however, public awareness and understanding of interstitial lung disease (ILD) remain limited. So, what exactly is interstitial lung disease?

What Is Interstitial Lung Disease?

Interstitial lung disease is a category of lung disorders. Currently, its detection rate has increased due to the widespread use of high-resolution computed tomography (HRCT). The interstitium refers to the tissue located between alveoli and surrounding structures, rich in blood vessels, lymphatic vessels, and various cells—including connective tissue. When pathological changes occur—such as excessive proliferation of connective tissue, increased elastic fibers, abnormal vascular proliferation, or inflammatory cell infiltration—the interstitium becomes altered, resulting in interstitial lung disease. Clinically, patients commonly present with cough, sputum production, dyspnea, extrapulmonary manifestations (e.g., skin rashes), and clubbing of the fingers. Specific symptoms vary depending on the underlying disease—for instance, smooth muscle hyperplasia may cause ventilatory dysfunction, which constitutes the hallmark functional impairment in ILD.

Treatment for interstitial lung disease includes pharmacotherapy and, in advanced cases, lung transplantation. During acute exacerbations, high-dose corticosteroid pulse therapy is often employed, sometimes combined with immunosuppressants such as azathioprine or cyclophosphamide. Antifibrotic agents like pirfenidone can help slow the decline in pulmonary function and reduce the frequency of acute exacerbations. If diffuse fibrotic changes involve both lungs and fail to respond adequately to medical therapy or other interventions, lung transplantation may be considered.

In daily life, patients should prioritize adequate rest and consume light, non-irritating foods while avoiding spicy or otherwise stimulating foods. We hope this information proves helpful to you.